• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Silk Road Medical Reports Fourth Quarter and Full Year 2023 Financial Results and Provides 2024 Financial Outlook

    2/28/24 4:05:00 PM ET
    $SILK
    Medical/Dental Instruments
    Health Care
    Get the next $SILK alert in real time by email

    SUNNYVALE, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (NASDAQ:SILK), a company focused on reducing the risk of stroke and its devastating impact, today reported financial results for the three months and full year ended December 31, 2023.

    "With the right team in place, broad reimbursement, and extensive evidence in support of TCAR, we are laser focused on deepening adoption in physicians who perform TCAR," said Chas McKhann, CEO of Silk Road Medical. "My experience thus far at Silk Road has only served to further validate the vast opportunity that we see for TCAR to benefit many more patients with carotid artery disease, and I'm excited by the underlying progress we are already making towards that end."

    Recent Business Highlights

    • Completed more than 25,000 TCAR procedures in 2023, bringing the cumulative total to over 85,000
    • Received expanded coverage for TCAR under a revised national coverage decision issued by CMS, further expanding access to TCAR and reducing administrative barriers
    • Initiated the limited market release of new tapered configurations for the Company's ENROUTE Transcarotid Stent System
    • Executed distribution agreements with Medico's Hirata in Japan and Genesis MedTech Group in China following clearance for the Company's ENROUTE Stent and ENROUTE Neuroprotection System in both countries

    Fourth Quarter 2023 Financial Results

    Revenue for the fourth quarter of 2023 was $47.3 million, an increase of $7.2 million or 18%, as compared to the fourth quarter of 2022. Growth was driven primarily by increased TCAR adoption.

    Gross profit for the fourth quarter of 2023 was $34.8 million compared to $29.1 million for the fourth quarter of 2022. Gross margin for the fourth quarter of 2023 increased to 74% compared to 73% for the fourth quarter of 2022, primarily due to an increase in production volumes.

    Operating expenses were $49.2 million for the fourth quarter of 2023 compared to $41.7 million in the fourth quarter of 2022, which represents an increase of 18%. The increase was primarily driven by increased headcount.

    Net loss was $13.0 million for the fourth quarter of 2023, or a loss of $0.33 per share, as compared to a loss of $12.6 million, or $0.34 per share, for the fourth quarter of 2022.

    Adjusted EBITDA was a loss of $4.1 million for the fourth quarter of 2023 compared to a loss of $4.4 million for the fourth quarter of 2022.

    For additional information regarding non-GAAP financial measures, see "Use of Non-GAAP Financial Measures" and "Reconciliation of GAAP Net Loss to Adjusted EBITDA" below.

    Full Year 2023 Financial Results

    Revenue for the full year 2023 was $177.1 million, an increase of $38.5 million or 28%, as compared to 2022. The increase was driven primarily by increased TCAR adoption.

    Gross profit for the full year 2023 was $127.1 million compared to $100.8 million for 2022. Gross margin for the full year 2023 decreased to 72% compared to 73% in 2022. The decrease in gross margin was driven primarily by unfavorable production variances.

    Operating expenses were $186.4 million for the full year 2023, compared to $152.8 million for 2022, which represents an increase of 22%. The increase was primarily driven by increased headcount.

    Net loss was $55.7 million in the full year 2023, or a loss of $1.44 per share, as compared to a loss of $55.0 million, or $1.54 per share, for 2022.

    Adjusted EBITDA was a loss of $17.7 million for the full year 2023, compared to a loss of $25.1 million for 2022.

    Cash, cash equivalents and investments were $190.9 million as of December 31, 2023.

    2024 Financial Guidance

    Silk Road Medical projects revenue for the full year 2024 to range from $194 million to $198 million.

    Conference Call

    Silk Road Medical will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET on Wednesday, February 28, 2024, to discuss its fourth quarter and full year 2023 financial results. Those interested in listening to the conference call should register online using this link. Participants are encouraged to register more than 15 minutes before the start of the call. A live and replay version of the webcast will be available at https://investors.silkroadmed.com and will remain available for at least 12 months.

    About Silk Road Medical

    Silk Road Medical, Inc. (NASDAQ:SILK), is a medical device company located in Sunnyvale, California and Plymouth, Minnesota, that is focused on reducing the risk of stroke and its devastating impact. The Company has pioneered a new approach for the treatment of carotid artery disease called TransCarotid Artery Revascularization (TCAR). TCAR is a clinically proven procedure combining surgical principles of neuroprotection with minimally invasive endovascular techniques to treat blockages in the carotid artery at risk of causing a stroke. For more information on how Silk Road Medical is delivering brighter patient outcomes through brighter clinical thinking, visit www.silkroadmed.com and connect on X, LinkedIn and Facebook.

    Forward-Looking Statements

    Statements contained in this press release that relate to future, not past, events are forward-looking statements under the Private Securities Litigation Reform Act of 1995, including Silk Road Medical's financial guidance and statements related to the future opportunity of its business. Forward-looking statements are based on current expectations of future events and often can be identified by words such as "expect," "should," "project," "anticipate," "intend," "will," "can," "may," "believe," "could," "continue," "outlook," "guidance," "future," other words of similar meaning or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Risks and uncertainties may cause Silk Road Medical's actual results to be materially different than those expressed in or implied by Silk Road Medical's forward-looking statements. For Silk Road Medical, such risks and uncertainties include, among others, future operating results and financial performance; the Company's success in retaining and recruiting key personnel; the ability to continue to grow the business and expand the use of TCAR; the ability to obtain an adequate supply of materials and components from its third-party suppliers; product development plans and the ability to commercialize new products in a timely manner; the success of current clinical trials; plans to conduct further clinical trials; the ability to obtain additional indications or new regulatory approvals or clearances for its products; market acceptance and use of its products by physicians; the ability to grow and leverage its commercialization infrastructure; the effect of increased competition; the effect of economic conditions and COVID-19 or similar pandemics on its business; government and third-party payer coverage and reimbursement and the ability to obtain and maintain intellectual property protection for its products. More detailed information on these and other factors that could affect Silk Road Medical's actual results are described in its filings with the U.S. Securities and Exchange Commission, including its most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission today, February 28, 2024. Silk Road Medical undertakes no obligation to update its forward-looking statements.

    Use of Non-GAAP Financial Measures

    To supplement its financial statements prepared in accordance with U.S. generally accepted accounting principles (GAAP), the Company uses adjusted EBITDA, which is a non-GAAP financial measure, in this press release. A reconciliation of non-GAAP adjusted EBITDA to GAAP net loss, which is the most directly comparable GAAP financial measure, is provided in the financial statement tables included in this press release, and investors are encouraged to review the reconciliation. Non-GAAP adjusted EBITDA is calculated by adding back to net loss or excluding, as appropriate, interest income and expense, provision for income taxes, and charges for depreciation and amortization and is further adjusted by adding back in or excluding, as appropriate, other income and expense and stock-based compensation. The Company believes the presentation of adjusted EBITDA provides useful information to investors as it provides visibility to the Company's underlying continuing operating performance from period to period by excluding the impact of certain items that are non-cash or non-recurring in nature or not related to the Company's core business operations. Adjusted EBITDA is also frequently used by analysts, investors and other interested parties to evaluate companies in the same industry. Management uses adjusted EBITDA internally for evaluation of the performance of the Company's business, including the allocation of resources.

    The Company's definition of adjusted EBITDA may differ from similarly titled measures used by others. Adjusted EBITDA should be considered only as a supplement to, and not as a substitute for, or superior to, net income or loss prepared in accordance with GAAP. Because adjusted EBITDA excludes the effect of items that increase or decrease the Company's reported results of operations, management strongly encourages investors to review, when they become available, the Company's financial statements and publicly filed SEC reports in their entirety.

    Investor Contact:

    Marissa Bych

    Gilmartin Group

    [email protected]

    Media:

    Michael Fanucchi

    Silk Road Medical

    [email protected]



    SILK ROAD MEDICAL, INC.
    Statements of Operations Data
    (unaudited, in thousands, except share and per share data)
                
     Three Months Ended Year Ended
     December 31, December 31,
      2023   2022   2023   2022 
    Revenue$47,270  $40,070  $177,134  $138,638 
    Cost of goods sold 12,468   10,979   50,048   37,876 
    Gross profit 34,802   29,091   127,086   100,762 
    Operating expenses:           
    Research and development 10,064   9,200   41,324   36,449 
    Selling, general and administrative 39,110   32,521   145,033   116,317 
    Total operating expenses 49,174   41,721   186,357   152,766 
    Loss from operations (14,372)  (12,630)  (59,271)  (52,004)
    Interest income 2,618   1,776   9,957   2,527 
    Interest expense (1,734)  (1,732)  (6,871)  (5,098)
    Loss on debt extinguishment —   —   —   (245)
    Other income (expense), net 477   (28)  442   (190)
    Net loss (13,011)  (12,614)  (55,743)  (55,010)
    Other comprehensive income (loss):           
    Unrealized gain (loss) on investments, net 356   25   238   (166)
    Other comprehensive income (loss) 356   25   238   (166)
                
    Comprehensive loss$(12,655) $(12,589) $(55,505) $(55,176)
                
    Net loss per share, basic and diluted$(0.33) $(0.34) $(1.44) $(1.54)
                
    Weighted average common shares used to compute net loss per share, basic and diluted 39,048,656   37,609,019   38,804,343   35,775,672 





    SILK ROAD MEDICAL, INC.
    Balance Sheets Data
    (unaudited, in thousands)
          
     December 31, 2023 December 31, 2022
    Assets     
    Current assets     
    Cash and cash equivalents$20,210  $55,358 
    Short-term investments 161,264   158,316 
    Accounts receivable, net 23,573   18,007 
    Inventories 29,876   19,293 
    Prepaid expenses and other current assets 5,912   3,924 
    Total current assets 240,835   254,898 
    Long-term investments 9,456   — 
    Property and equipment, net 8,114   9,372 
    Restricted cash —   155 
    Other non-current assets 6,904   5,260 
    Total assets$265,309  $269,685 
    Liabilities and stockholders' equity     
    Current liabilities     
    Accounts payable$5,676  $2,523 
    Accrued liabilities 24,607   21,965 
    Total current liabilities 30,283   24,488 
    Long-term debt 75,626   74,596 
    Other liabilities 8,249   6,726 
    Total liabilities 114,158   105,810 
    Stockholders' equity     
    Preferred stock, $0.001 par value —   — 
    Common stock, $0.001 par value 39   38 
    Additional paid-in capital 550,495   507,715 
    Accumulated other comprehensive income (loss) 72   (166)
    Accumulated deficit (399,455)  (343,712)
    Total stockholders' equity 151,151   163,875 
    Total liabilities and stockholders' equity$265,309  $269,685 





    SILK ROAD MEDICAL, INC.
    Reconciliation of GAAP Net Loss to Adjusted EBITDA
    (unaudited, in thousands)
                
     Three Months Ended Year Ended
     December 31, December 31,
      2023   2022   2023   2022         
    GAAP Net Loss$(13,011) $(12,614) $(55,743) $(55,010)
    Non-GAAP Adjustments:           
    Interest (income) expense, net (884)  (44)  (3,086)  2,571 
    Depreciation and amortization 656   661   2,696   2,127 
    Other (income) expense, net (477)  28   (442)  190 
    Stock-based compensation expense 9,609   7,546   38,893   25,023 
    Adjusted EBITDA$(4,107) $(4,423) $(17,682) $(25,099)



    Primary Logo

    Get the next $SILK alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $SILK

    DatePrice TargetRatingAnalyst
    7/11/2024Buy → Sell
    Argus
    3/7/2024$24.00Hold → Buy
    Argus
    1/19/2024$9.00 → $20.00Hold → Buy
    Stifel
    1/3/2024$20.00Buy
    Lake Street
    10/24/2023Underperform → Peer Perform
    Wolfe Research
    10/11/2023$54.00 → $14.00Buy → Neutral
    B. Riley Securities
    10/11/2023Buy → Neutral
    CL King
    10/11/2023$45.00 → $12.00Buy → Hold
    Stifel
    More analyst ratings

    $SILK
    SEC Filings

    See more
    • SEC Form 15-12G filed by Silk Road Medical Inc.

      15-12G - Silk Road Medical Inc (0001397702) (Filer)

      9/27/24 4:00:39 PM ET
      $SILK
      Medical/Dental Instruments
      Health Care
    • SEC Form EFFECT filed by Silk Road Medical Inc.

      EFFECT - Silk Road Medical Inc (0001397702) (Filer)

      9/24/24 12:15:03 AM ET
      $SILK
      Medical/Dental Instruments
      Health Care
    • SEC Form 25-NSE filed by Silk Road Medical Inc.

      25-NSE - Silk Road Medical Inc (0001397702) (Subject)

      9/17/24 9:33:30 AM ET
      $SILK
      Medical/Dental Instruments
      Health Care

    $SILK
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Ballinger Kevin J. bought $198,783 worth of shares (11,700 units at $16.99), increasing direct ownership by 192% to 17,807 units (SEC Form 4)

      4 - Silk Road Medical Inc (0001397702) (Issuer)

      3/7/24 6:01:30 AM ET
      $SILK
      Medical/Dental Instruments
      Health Care

    $SILK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Silk Road Medical downgraded by Argus

      Argus downgraded Silk Road Medical from Buy to Sell

      7/11/24 7:47:06 AM ET
      $SILK
      Medical/Dental Instruments
      Health Care
    • Silk Road Medical upgraded by Argus with a new price target

      Argus upgraded Silk Road Medical from Hold to Buy and set a new price target of $24.00

      3/7/24 7:36:37 AM ET
      $SILK
      Medical/Dental Instruments
      Health Care
    • Silk Road Medical upgraded by Stifel with a new price target

      Stifel upgraded Silk Road Medical from Hold to Buy and set a new price target of $20.00 from $9.00 previously

      1/19/24 8:14:13 AM ET
      $SILK
      Medical/Dental Instruments
      Health Care

    $SILK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Zurbay Donald returned 12,610 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - Silk Road Medical Inc (0001397702) (Issuer)

      9/18/24 9:12:36 PM ET
      $SILK
      Medical/Dental Instruments
      Health Care
    • Director Weatherman Elizabeth H returned 155,004 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - Silk Road Medical Inc (0001397702) (Issuer)

      9/18/24 9:08:24 PM ET
      $SILK
      Medical/Dental Instruments
      Health Care
    • Director Lasersohn Jack W returned 16,735 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - Silk Road Medical Inc (0001397702) (Issuer)

      9/18/24 9:01:12 PM ET
      $SILK
      Medical/Dental Instruments
      Health Care

    $SILK
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Boston Scientific Announces Results for Third Quarter 2024

      MARLBOROUGH, Mass., Oct. 23, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $4.209 billion during the third quarter of 2024, growing 19.4 percent on a reported basis, 19.5 percent on an operational1 basis and 18.2 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $469 million or $0.32 per share (EPS), compared to $505 million or $0.34 per share a year ago, and achieved adjusted3 EPS of $0.63 for the period, compared to $0.50 a year ago.

      10/23/24 6:30:00 AM ET
      $BSX
      $SILK
      Medical/Dental Instruments
      Health Care
    • Boston Scientific Closes Acquisition of Silk Road Medical, Inc.

      MARLBOROUGH, Mass., Sept. 17, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of Silk Road Medical, Inc. (NASDAQ:SILK), a medical device company that pioneered a new approach for stroke prevention and the treatment of carotid artery disease through a minimally invasive procedure called transcarotid artery revascularization (TCAR). "Completing this acquisition enables Boston Scientific to strengthen our vascular technology solutions by bringing the innovative TCAR platform to a greater number of physicians and their pa

      9/17/24 8:31:00 AM ET
      $BSX
      $SILK
      Medical/Dental Instruments
      Health Care
    • SILK Alert: Monsey Firm of Wohl & Fruchter Renews Investigation of the Proposed Sale of Silk Road Medical to Boston Scientific

      MONSEY, N.Y., Aug. 19, 2024 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP has renewed its investigation into the fairness of the proposed sale of Silk Road Medical, Inc. (NASDAQ:SILK) ("SILK") to Boston Scientific Corporation for $27.50 per share in cash. On July 29, 2024, SILK filed a definitive proxy concerning the proposed sale with the SEC. Based on our review of the proxy, we have renewed our investigation into whether there are any undisclosed potential conflicts of interest. If you remain a SILK shareholder and question the fairness of the price or have any other concerns, you may contact our firm at the following link to discuss your legal rights at no charge: https:/

      8/19/24 9:31:00 AM ET
      $SILK
      Medical/Dental Instruments
      Health Care

    $SILK
    Leadership Updates

    Live Leadership Updates

    See more
    • Silk Road Medical Names Chas McKhann Chief Executive Officer

      SUNNYVALE, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (NASDAQ:SILK) ("Silk Road" or the "Company"), a company focused on reducing the risk of stroke and its devastating impact, today announced that Chas McKhann has been appointed Chief Executive Officer (CEO), effective immediately. Mr. McKhann is an accomplished leader with more than 25 years of experience in the medical device industry, including C-suite positions at seven public and private companies. Most recently, Mr. McKhann served as President and CEO of Apollo Endosurgery (acquired by Boston Scientific in April 2023), where he created and led a transformational growth strategy for the company's minimal

      11/2/23 8:00:00 AM ET
      $SILK
      Medical/Dental Instruments
      Health Care
    • Silk Road Medical Announces Retirement of CEO Erica Rogers

      Working with Leading Executive Search Firm to Identify Successor SUNNYVALE, Calif., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (NASDAQ:SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced that CEO Erica Rogers plans to retire from the Company following the completion of a succession process. The Company is working with Spencer Stuart, a leading executive search firm. To ensure a smooth transition, Ms. Rogers will remain as President and CEO of the Company until her successor is appointed. "I'd like to thank Erica for her tremendous contributions to Silk Road over the last 11 years. Erica has been integral in leading and expand

      10/10/23 4:20:00 PM ET
      $SILK
      Medical/Dental Instruments
      Health Care
    • Silk Road Medical Names Dr. Tanisha Carino to Board of Directors

      SUNNYVALE, Calif., July 26, 2021 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (NASDAQ:SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced that it has appointed Dr. Tanisha Carino to its Board of Directors. Tanisha Carino, Ph.D., is a health policy expert bringing over 20 years of experience driving growth and impact across multiple healthcare leadership positions in the government, private, and non-profit sectors. She most recently served as Executive Vice President, Chief Corporate Affairs Officer of Alexion, a Fortune 500 biotechnology company focused on rare disease, which was recently acquired by AstraZeneca.   Prior to Alexion, she serv

      7/26/21 4:05:00 PM ET
      $SILK
      Medical/Dental Instruments
      Health Care

    $SILK
    Financials

    Live finance-specific insights

    See more
    • Boston Scientific Announces Results for Third Quarter 2024

      MARLBOROUGH, Mass., Oct. 23, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $4.209 billion during the third quarter of 2024, growing 19.4 percent on a reported basis, 19.5 percent on an operational1 basis and 18.2 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $469 million or $0.32 per share (EPS), compared to $505 million or $0.34 per share a year ago, and achieved adjusted3 EPS of $0.63 for the period, compared to $0.50 a year ago.

      10/23/24 6:30:00 AM ET
      $BSX
      $SILK
      Medical/Dental Instruments
      Health Care
    • Boston Scientific Announces Results for Second Quarter 2024

      MARLBOROUGH, Mass., July 24, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) generated net sales of $4.120 billion during the second quarter of 2024, growing 14.5 percent on a reported basis, 16.1 percent on an operational1 basis and 14.7 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $324 million or $0.22 per share (EPS), compared to $261 million or $0.18 per share a year ago, and achieved adjusted3 EPS of $0.62 for the period, compared to $0.53 a year ago.

      7/24/24 6:30:00 AM ET
      $BSX
      $SILK
      Medical/Dental Instruments
      Health Care
    • Silk Road Medical Reports First Quarter 2024 Financial Results

      SUNNYVALE, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (NASDAQ:SILK), a company focused on reducing the risk of stroke and its devastating impact, today reported financial results for the three months ended March 31, 2024. "Our team delivered a strong start to 2024 as we deepened relationships with the physicians we serve and continued broadening our patient impact," said Chas McKhann, CEO of Silk Road Medical. "In the first quarter, we made meaningful commercial progress while also taking steps toward sustainable profitability. We enter the second quarter feeling energized by TCAR's outstanding value proposition for physicians and patients and in our opportun

      4/30/24 4:05:00 PM ET
      $SILK
      Medical/Dental Instruments
      Health Care

    $SILK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Silk Road Medical Inc.

      SC 13D/A - Silk Road Medical Inc (0001397702) (Subject)

      9/19/24 8:16:37 AM ET
      $SILK
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13D filed by Silk Road Medical Inc.

      SC 13D - Silk Road Medical Inc (0001397702) (Subject)

      8/12/24 4:21:48 PM ET
      $SILK
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Silk Road Medical Inc.

      SC 13G/A - Silk Road Medical Inc (0001397702) (Subject)

      7/10/24 1:45:37 PM ET
      $SILK
      Medical/Dental Instruments
      Health Care